Press
Leslie J. De Groot MD, 1928-2018
Posted on October 23, 2018 by Annie De GrootLeslie J. DeGroot MD (“Les”) was born on a dairy farm in Fort Edward NY in 1928, dedicated his life to thyroid disease research and endocrinology and died soon after his 90th birthday, on October 23, 2018 in Nonquitt, Massachusetts, surrounded by his many loving grandchildren, children and his wife.Read moreBreaking News: FDA awards $1 million to EpiVax, CUBRC, to assess generic peptide drugs
Posted on October 5, 2018 by Annie De GrootThis original article was published on October 2nd, 2018 in ConvergenceRI. PROVIDENCE, RI – The U.S. Food and Drug Administration announced on Tuesday, Oct. 2, that the federal agency has awarded EpiVax and CUBRC a $1 million contract over two years to establish best practices and procedures to evaluate generic peptide drugs for immunogenic potential and related ...Read morePANDA: The Newest Product at EpiVax
Posted on October 2, 2018 by Annie De GrootEpiVax has been awarded a $1 million contract from the Food and Drug Administration (FDA) to demonstrate and validate the best practices and procedures for assessing generic peptide drugs and related impurities for immunogenic potential.Read moreEpiVax Oncology Completes a $1.2M Bridge Financing
Posted on June 13, 2018 by Sarah MonizNEW YORK CITY AND PROVIDENCE, RI., June 12, 2018 (BUSINESS WIRE) — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate NY Seed Fund and Horatio Ventures NYC. EpiVax Oncology, Inc. (EO) is developing precision cancer immunotherapies based on Neo-Epitopes ...Read moreEpiVax Opens New Headquarters and Celebrates 20 Years of Fearless Science
Posted on June 11, 2018 by Sarah MonizPROVIDENCE, R.I., June 11, 2018 — EpiVax announces their move to a new headquarters at 188 Valley Street, in the “Rising Sun” complex, a former wool mill in the Olneyville section of Providence, Rhode Island. The privately held bioinformatics company is also celebrating its 20th anniversary. The mission of EpiVax is to “improve human health everywhere” through ...Read more$325K NIH Grant to EpiVax to Enable Development of Personalized Risk Assessment Tool for Enzyme Replacement Therapy in Pompe Disease
Posted on May 18, 2018 by Sarah MonizPROVIDENCE, R.I., May 18, 2018 /PRNewswire/ — The National Institutes of Health (NIH) has awarded EpiVax, Inc. (“EpiVax”), experts in the field of immunogenicity risk assessment, a $324,980 Small Business Innovation Research (SBIR) grant. The funding will enable EpiVax to further develop the new Personalized Immunogenicity Assessment (PIMA) tool, for the individualized risk assessment of ...Read moreEpiVax and GAIA Vaccine Foundation Celebrate Women’s Achievements Throughout History and Across Nations
Posted on March 8, 2018 by Sarah MonizPROVIDENCE, R.I., March 9, 2018 /PRNewswire/ — EpiVax Inc., (“EpiVax”) an innovative Rhode Island-based biotechnology company, has a lot to celebrate on International Women’s Day. The company, founded and led by Dr. Annie De Groot, boasts a female-majority work force and appears multiple times in the Providence Business News Book of Lists for Rhode Island: Top Private Companies (by revenue), Fastest ...Read moreEpiVax Awarded Grant to Develop New Graves’ Disease Therapy
Posted on December 19, 2017 by Sarah MonizEpiVax Awarded Grant to Develop New Graves' Disease TherapyRead moreEpiVax Launches Precision Immunotherapy Venture
Posted on September 25, 2017 by Annie De GrootEpiVax Oncology Press Release Sept 25 2017 Sept 25, 2017 (Providence, RI) – EpiVax, Inc., a leader in the fields of immunogenicity assessment, vaccine design, and immune-engineering today announced the launch of EpiVax Oncology Inc., a company focused on the development of personalized therapeutic cancer vaccines. EpiVax has provided $500,000 in seed funding and has provided ...Read moreEpiVax Awarded Grant For Vaccine Engineering
Posted on September 17, 2017 by Annie De Groot$5.8 MILLION AWARDED FOR VACCINE ENGINEERING WILL USE “IMMUNE HISTORY” TO PROTECT AGAINST BIRD FLU, A COLLABORATION LED BY EPIVAX PROVIDENCE, R.I., Sept. 18, 2017– EpiVax, Inc. (“EpiVax”) a pioneer in the fields of bioinformatics and immune engineering, today announced a new NIH-funded collaboration to develop a protective avian influenza A (H7N9) vaccine. H7N9 is distantly related to seasonal influenza ...Read moreEpiVax and EpiVax Oncology: Ready to Take on Cancer
Posted on August 22, 2017 by Katie PorterEpiVax has carved out a niche in the biotech and immunoinformatics industry with our innovative tools and discoveries. Well-situated on a trajectory Dr. De Groot described as “upward and stable,” EpiVax is now gearing up to launch a venture-backed spinoff called EpiVax Oncology. EpiVax Oncology Inc. is a newly created, wholly owned subsidiary of EpiVax Inc. ...Read moreEpiVax: Best Place to Work 2017!
Posted on August 3, 2017 by Annie De GrootEpiVax: Best Place to Work 2017!Read moreEpiVax Awarded New “Innovation Voucher”
Posted on August 3, 2017 by epivax3Accelerating the Development of a Game Changing Cancer Therapy PROVIDENCE, R.I., Aug. 3, 2017 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today announced it received funding from the Rhode Island Commerce Corporation to accelerate the development of personalized cancer vaccines using in silico methods. In partnership with Rhode Island Hospital, EpiVax’s innovative project aims to identify cancer-specific targets, or neoantigens, capable of directing ...Read moreOptimized H7N9 induces higher Ab in humanized, but not standard, mice
Posted on May 24, 2017 by Annie De GrootA new article in Nature Scientific Reports (doi: 10.1038/s41598-017-01372-5) entitled A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines may explain why H7N9 influenza vaccines are consistently less immunogenic in humans than vaccines developed for other subtypes of influenza. In previous work, we identified a key T-cell epitope in H7 hemagglutinin (HA) that ...Read moreHappy Birthday EpiVax! We’re Celebrating With a New Look!
Posted on May 18, 2017 by Katie PorterNineteen years ago, on May 18th, 1998, EpiVax incorporated as a biotechnology company. In 2017, our business has never been stronger: the team is stacked with talent, collaborations are abundant and world-wide, and our in silico user base is extensive. We were recently recognized as one of the 2017 Best Places to Work in Rhode Island, we are ...Read more
Join our newsletter
We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content. Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.